The RAPS EU Board of Directors is the governing, policy-making and strategic body that guides RAPS in serving the regulatory professional in Europe. The EU Board of Directors has the legal and fiduciary responsibility to ensure the long-term viability and integrity of RAPS in Europe. The EU Board of Directors plays an integral role in maintaining a system of checks and balances that enables the organization to make strategic business decisions in that region.

Salma Michor

Salma Michor, PhD, MSc, MBA, CMgr, RAC Chair

Salma Michor is founder and CEO of Michor Consulting and Trade Services GmbH, serving such clients as Johnson & Johnson, Novartis, Pfizer and CSL Behring. Previously, Michor worked for Chiesi-Torrex, Wyeth Whitehall Export Croma Pharma GmbH. She teaches regulatory affairs and clinical strategies at the University of Krems, Austria, and is an independent expert to the European Commission. Michor is a member of the RAPS European Board. She holds a PhD in Bio engineering and an MSc in food and biotechnology from the University of Applied Life Sciences in Vienna, Austria; an MSc from King’s College, University of London in food technology; and an MBA from Open University and has earned the RAC (EU and Global). She is a Chartered Manager and a fellow of the Chartered Management Institute.

Gert Bos

Gert Bos, PhD, FRAPS — Director

Gert Bos, PhD, FRAPS, is CSO, executive director and partner with Qserve Group in the Netherlands. He is an expert in European regulations with 28 years of experience in life sciences, including 15 years as auditor, product reviewer, regulatory specialist, and head of notified body. Bos has been leading the notified bodies in Brussels for many years and has strongly supported the regulatory debate with the EU Commission, EU Parliament, and the EU Council of Ministers. He has a PhD in biomaterial sciences, and postdoctoral degrees in controlled release of drugs and gene therapy. He is a RAPS Fellow, a founding member of the RAPS European Council, a founding board member of the RAPS Netherlands Chapter and the current president of the RAPS Board of Directors.

Sophie Tabutin

Sophie Tabutin, PharmD, QP — Director

Sophie Tabutin, PharmD, QP, leads the European and MEA regulatory affairs team at W. L. Gore & Associates. Previously, Tabutin worked for BSI Notified Body, first, as a product reviewer, technical expert, project manager and QMS assessor, then as the Notified Body regulatory lead. Tabutin, a qualified pharmacist, has extensive experience in both MDR and IVDR. Prior to that, she worked with top pharmaceutical companies to develop and produce investigational drugs and conduct clinical research.


Susana de Azevedo Wäsch

Dr. Susana de Azevedo Wäsch — Director

Susana de Azevedo Wäsch is vice president of quality management, regulatory affairs and medical affairs with Ypsomed AG. She has more than 25 years of experience in medical devices, pharmaceuticals, and biotechnology. Wäsch is experienced in the areas of regenerative medicine, implants, drug-device combination products and infusion pumps. Prior to Ypsomed, she worked at Geistlich Pharma AG, Switzerland; Eidgenössische Technische Hochschule Zürich; Lonza Visp, Switzerland; the European Bioinformatics Institute; and the Center for Advanced Research in Biotechnology. She holds an MSc from the Ecole Supérieure de Biotechnologies Strasbourg, France; a PhD from the Institute of Microbiology at the Swiss Federal Institute of Technology; and an MBA from the Executive School of Management, Technology and Law in St. Gallen, Switzerland.

Bill McMoil

Bill McMoil RAPS Executive Director

Bill McMoil joined RAPS in 2017 as vice president of finance, information technology and operations. He was named executive director in December 2022. Since joining RAPS, McMoil has grown the organization from 26,000 to 30,000 members globally; staff from 40 to 50; and annual revenue by 21%. He has championed innovative and effective solutions to address the diverse educational needs of the regulatory profession. He has built a vibrant collaboration with the RAPS volunteer base (boards, committees, chapters, etc.) in support of RAPS’ diverse, and geographically distributed community. McMoil has also ensured that RAPS promotes itself as an ethical, neutral, and non-advocacy community for its more than 30,000-strong global regulatory members to connect, learn and share ideas and expanded its reach and engagement in Europe.

Learn more about RAPS